文献速递慢病防控与筛查免疫规划

将DPP4的B细胞表位与肽IA2(5)-P2-1偶联构建新型疫苗可显著控制NOD小鼠的1型糖尿病

Construction of a novel vaccine by conjugating a B-cell epitope of DPP4 to peptide IA2(5)-P2-1 to significantly control type 1 diabetes in NOD mice.
PubMed 文献 · Vaccine · 2017-11-21

本研究构建了由DPP4肽、胰岛素瘤抗原2(IA-2)抗糖尿病B细胞表位及人热休克蛋白60(HSP60)P277肽的Th2表位(P2:IPALDSLTPANED)组成的多表位疫苗。在非肥胖糖尿病(NOD)小鼠中免疫可诱导特异性抗DPP4抗体、抑制血浆DPP4活性、升高血清GLP-1水平,且抗体滴度与免疫剂量(20μg、100μg)相关。接种该疫苗显著控制血糖水平、改善葡萄糖偏移并增加体内胰岛素水平,同时降低糖尿病和胰岛炎发生率,诱导脾T细胞增殖和耐受;与P277组和对照组相比,D41-IA2(5)-P2-1处理小鼠IFN-γ分泌减少、IL-10显著增加。免疫组化和流式细胞术显示NOD小鼠Th1/Th2再平衡。作者认为该多表位疫苗可能成为1型糖尿病有前景的治疗方法。

要点

  • 多表位疫苗D41-IA2(5)-P2-1免疫NOD小鼠可诱导特异性抗DPP4抗体并抑制血浆DPP4活性。
  • 该疫苗显著控制血糖、改善葡萄糖偏移、增加胰岛素水平,并降低糖尿病和胰岛炎发生率。
  • 疫苗诱导脾T细胞增殖和耐受,使IFN-γ减少、IL-10增加,并再平衡Th1/Th2。

核心结论

  • 作者认为该多表位疫苗可能作为1型糖尿病有前景的治疗方法。

研究设计与样本

  • 本研究为动物实验,在非肥胖糖尿病(NOD)小鼠中构建并评价多表位疫苗D41-IA2(5)-P2-1。
  • 疫苗由DPP4肽、胰岛素瘤抗原2(IA-2)抗糖尿病B细胞表位及人热休克蛋白60(HSP60)P277肽的Th2表位(P2:IPALDSLTPANED)组成。
  • 免疫剂量包括20μg和100μg,抗体滴度与免疫剂量相关。

主要发现

  • 免疫NOD小鼠成功诱导特异性抗DPP4抗体,抑制血浆DPP4活性,升高血清GLP-1水平。
  • 接种疫苗显著控制血糖水平、改善葡萄糖偏移并增加体内胰岛素水平。
  • 与P277组和对照组相比,D41-IA2(5)-P2-1处理小鼠IFN-γ分泌减少、IL-10显著增加。
  • 免疫组化和流式细胞术显示NOD小鼠Th1/Th2再平衡。
  • 疫苗降低糖尿病和胰岛炎发生率,并诱导脾T细胞增殖和耐受。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Type 1 diabetes is a chronic organ-specific autoimmune disease in which selective destruction of insulin-producing β cells leads to impaired glucose metabolism and its attendant complications. IA2(5)P2-1, a potent immunogenic carrier which designed by our laboratory, can induce high titer specific antibodies when carry a B cell epitope, such as B cell epitopes of DPP4, xanthine oxidase, and Urate transporter protein. In this report, we describe a novel multi-epitope vaccine composing a peptide of DPP4, an anti-diabetic B epitope of Insulinoma antigen-2(IA-2) and a Th2 epitope (P2:IPALDSLTPANED) of P277 peptide in human heat shock protein 60 (HSP60). Immunization with the multi-epitope vaccine in non-obese diabetic (NOD) mice successfully induced specific anti-DPP4 antibody, inhibited plasma DPP4 activity, and increased serum GLP-1 level. Moreover, this antibody titer was correlated with the dose of immunization (20μg, 100μg). Inoculation of this vaccine in NOD mice significantly control blood glucose level, improved glucose excursion and increased insulin level in vivo. Consistent with a lower diabetic and insulitis incidence, a induced splenic T cells proliferation and tolerance were observed. IFN-γ secretion reduced and IL-10 increased significantly in the D41-IA2(5)-P2-1 treated mice compared to P277 and control group due to the potential immunomodulatory effect of the epitope in the vaccine. Immunohistochemical analysis and cytometry showed a rebalance of Th1/Th2 in NOD mice. Our results demonstrate that this multi-epitope vaccine may serve as a promising therapeutic approach for type 1 diabetes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Li Y, Cao H, Li Y, et al. Construction of a novel vaccine by conjugating a B-cell epitope of DPP4 to peptide IA2(5)-P2-1 to significantly control type 1 diabetes in NOD mice. Vaccine. 2017. PMID: 29169891. doi:10.1016/j.vaccine.2017.10.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。